Paeoniflorin could activate PI3K/Akt signaling pathway to protect the PC12 cell injury induced by Aβ25-35.Paeoniflorin most likely contributes to the therapy for liver disease by exerting anti-inflammatory effects on HHSECs through blocking IL-8 secretion via downregulation of ERK1/2 and Akt.PF alleviates psoriatic skin lesions by inhibiting inflammation, which provides new insights into the immunomodulatory effect of PF in psoriasis treatment.Paeoniflorin pretreatment protects mice against Con A-induced liver injury via inhibition of several inflammatory mediators and, at least in part, by suppressing CD4(+), CD8(+) and NKT cell infiltration in liver. The beneficial effect of paeoniflorin may be related to the downregulation of TLR4 expression and the inhibition of NF-κB activation.Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α expression partly through mTOR pathway and paeoniflorin may be a potential therapeutic agent for liver fibrosis.
|Cell lines||PC12 cells|
|Preparation method||Cell Viability Assessment
Cell viability was measured using a quantitative colori-metric assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-nyl tetrazolium bromide (MTT) (Sigma-Aldrich, USA) as reported previously (Mosmann 1983). Briefly, cells were seeded into collagen I-coated 96-well plates at a density of 1*104 per well. At the completion of the 24-h treatment, 10 μL MTT solution (5 mg/mL) was added. Following incubation for 4 h at 37 ℃, 100 μL dimethyl sulfoxide (DMSO) was used to dissolve crystals. The absorbance was measured using a microplate reader (Bio-Rad, USA) and cell viability was expressed as a percentage of control value.
|Concentrations||0, 25, 50, 100, 200 and 400 μM|
|Incubation time||24 h|
|Animal models||Adult male Sprague-Dawley rats|
|Formulation||PBS, pH 7.5, 0.1 M at a concentration of 200 μg/μL|
|Dosages||15 mg/kg and 30 mg/kg for 20 consecutive days|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Paeoniflorin diminishes ConA-induced IL-8 production in primary human hepatic sinusoidal endothelial cells in the involvement of ERK1/2 and Akt phosphorylation.
Gong WG, et al. Int J Biochem Cell Biol. 2015 Mar 3;62:93-100. PMID: 25748730.
Paeoniflorin inhibits skin lesions in imiquimod-induced psoriasis-like mice by downregulating inflammation.
Sun Y, et al. Int Immunopharmacol. 2015 Feb;24(2):392-9. PMID: 25576402.
Paeoniflorin protects against concanavalin A-induced hepatitis in mice.
Chen M, et al. Int Immunopharmacol. 2015 Jan;24(1):42-9. PMID: 25479726.
Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway.
Zhao Y, et al. Fitoterapia. 2014 Dec;99:318-27. PMID: 25454463.
Paeoniflorin, a natural neuroprotective agent, modulates multiple anti-apoptotic and pro-apoptotic pathways in differentiated PC12 cells.
Wang D, et al. Cell Mol Neurobiol. 2013 May;33(4):521-9. PMID: 23436209.
Paeoniflorin attenuates amyloid-beta peptide-induced neurotoxicity by ameliorating oxidative stress and regulating the NGF-mediated signaling in rats.
Lan Z, et al. Brain Res. 2013 Mar 1;1498:9-19. PMID: 23295189.
|Related Akt Products|
Afuresertib hydrochloride is an orally bioavailable, potent and ATP-competitive inhibitor of the serine/threonine protein kinase Akt with potential antineoplastic activity.
Miransertib, also known as ARQ 092, is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).
GSK2141795 is a potent and selective pan-Akt inhibitor with IC50 values of 180 nM for Akt1, 328 nM for Akt2, and 38 nM for Akt3 respectively (Clinical phase 1).
GDC-0068(RG 7440) 2Hcl is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA.
Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.